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Major depressive disorder (MDD) is associated with cognitive impairments that may
contribute to poor functional outcomes. Clinical data suggests that the multimodal
antidepressant vortioxetine attenuates some cognitive impairments in MDD patients,
but the mechanistic basis for these improvements is unclear. One theory suggests
that vortioxetine improves cognition by suppressing γ-amino butyric acid (GABA)ergic
neurotransmission, thereby increasing glutamatergic activation. Vortioxetine’s effects on
cognition, GABA and glutamate neurotransmission have been supported in separate
experiments, but no empirical work has directly connected vortioxetine’s cognitive
effects to those on GABA and glutamate neurotransmission. In this paper, we attempt
to bridge this gap by evaluating vortioxetine’s effects in the subchronic PCP (subPCP)
model, which induces impaired cognitive function and altered GABA and glutamate
neurotransmission. We demonstrate that acute or subchronic vortioxetine treatment
attenuated subPCP-induced deficits in attentional set shifting (AST) performance, and
that the selective 5-HT3 receptor antagonist ondansetron or the 5-HT reuptake inhibitor
escitalopram could mimic this effect. Furthermore, acute vortioxetine treatment reversed
subPCP-induced object recognition (OR) deficits in rats, while subchronic vortioxetine
reversed subPCP-induced Object Recognition and object placement impairments in
mice. Finally, subPCP treatment reduced GABAB receptor expression in a manner
that was insensitive to vortioxetine treatment, and subchronic vortioxetine treatment
alone, but not in combination with subPCP, significantly increased GABA’s affinity for the
GABAA receptor. These data suggest that vortioxetine reverses cognitive impairments
in a model associated with altered GABA and glutamate neurotransmission, further
supporting the hypothesis that vortioxetine’s GABAergic and glutamatergic effects are
relevant for cognitive function.
Keywords: vortioxetine, subchronic PCP, attentional set-shifting test, novel object recognition, novel object
placement, serotonin, GABA
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effects on cognitive function, and toward this end several
mechanistic hypotheses have been advanced, which we do
not consider to be mutually exclusive. Among these are
hypotheses suggesting that vortioxetine improves cognitive
function via increases in acetylcholinergic neurotransmission
(Mork et al., 2013), a histamine/orexin-dependent mechanism
(Smagin et al., 2016), or an indirect, regionally selective increase
in glutamate neurotransmission (Dale et al., 2016; Pehrson
et al., 2016b). Non-clinical experiments from this laboratory
have since suggested that acetylcholinergic neurotransmission
is probably not a major cause of vortioxetine’s cognitive effects
after chronic administration (Pehrson et al., 2016a), while the
histamine/orexin hypothesis remains untested.
But there is accreting mechanistic evidence that
vortioxetine can modulate γ-aminobutyric acid (GABA)
and glutamate neurotransmission. Electrophysiological evidence
demonstrates that vortioxetine suppresses inhibitory GABAergic
neurotransmission via its potent antagonist effects at 5-HT3
receptors (Dale et al., 2014), and concomitantly increases
pyramidal neuron firing under acute or subchronic dosing
conditions (Riga et al., 2016, 2017). However, there is currently
little behavioral evidence specifically supporting the notion
that vortioxetine’s effects on these neurotransmitter systems are
relevant for cognitive function.
The subchronic phencyclidine (PCP) administration model
has a long history in non-clinical neuroscience, and has been
used extensively as a putative model of schizophrenia. This
theoretical conception of the subchronic PCP (subPCP) model
is based on early observations that humans who abuse PCP
over long periods can develop symptoms mimicking some
aspects of schizophrenia, including positive symptoms like
paranoia and auditory hallucinations, and most importantly
for our purposes, persistent cognitive dysfunction featuring
impaired executive function and memory (Jentsch and Roth,
1999). Importantly, rodent studies of subPCP-induced cognitive
impairments commonly replicate dysfunction in these cognitive
domains (for example, Redrobe et al., 2012).
Our interest in the subPCP treatment regimen as a model
of cognitive dysfunction was driven by its complex mechanistic
effects on GABA and glutamate neurotransmission, rather
than its theoretical conception as a model for schizophrenia.
Subchronic treatment with non-competitive NMDA receptor
antagonists is associated with a variety of changes in GABAergic
neurotransmission. For example, several research groups have
observed reductions in parvalbumin (PV) immunoreactivity
(IR) (Pratt et al., 2008; Redrobe et al., 2012), and Kv3.1
channel expression after subchronic PCP treatment (Pratt et al.,
2008), suggesting altered function in fast-spiking GABAergic
interneurons such as cortical basket and chandelier cells.
Additionally, repeated NMDA receptor antagonism is associated
with increases in binding (Kim et al., 2000) or KD (Beninger
et al., 2010) at the orthosteric GABAA receptor site, as well as
altered expression of genes encoding GABAA receptor subunits
(Kim et al., 2000). Similarly, subPCP-treated rodents have an
increased threshold for inducing long-term potentiation and
increased inhibitory postsynaptic currents (IPSCs) recorded
from pyramidal neurons in the Cornu Ammonis area 1 (CA1)

INTRODUCTION
Dysfunction in cognitive domains such as executive function
and memory are a common feature of psychiatric illness,
including major depressive disorder (MDD; McIntyre et al.,
2013). Cognitive impairments in MDD patients may predict poor
treatment response (Dunkin et al., 2000; Withall et al., 2009), and
are associated with reduced functional outcomes (Jaeger et al.,
2006). Additionally, the most commonly used antidepressants
have a limited ability to improve cognitive symptoms. As a
result, these cognitive impairments tend to remain prominent
after mood symptoms have begun to recede (Herrera-Guzman
et al., 2009, 2010). Thus, MDD-associated cognitive dysfunction
is increasingly viewed as an important target for pharmacological
remediation.
Vortioxetine is a multimodal antidepressant that acts
as an agonist at 5-HT1A receptors, a partial agonist at
5-HT1B receptors, an antagonist at 5-HT1D , 5-HT3 , and 5-HT7
receptors, and as an inhibitor at the serotonin (5-HT)
reuptake protein (SERT; Sanchez et al., 2015). A recent metaanalysis of three randomized placebo controlled clinical trials
in MDD patients demonstrated that vortioxetine induced
significant improvements compared to placebo in the digitsymbol substitution test, a putative measure of processing speed
and executive function, independently of its effects on mood
(McIntyre et al., 2016). Additionally, post hoc analyses from
several clinical trials support a role for vortioxetine in improving
executive function (Harrison et al., 2016). Clinical studies
have also demonstrated that vortioxetine significantly improves
memory performance in the Ray Auditory Verbal Learning test
(Katona et al., 2012; McIntyre et al., 2014). These results are
supported by non-clinical data (i.e., data from studies in animals)
suggesting that vortioxetine can improve aspects of executive
function (Wallace et al., 2014) and memory (Mork et al., 2013;
du Jardin et al., 2014; Jensen et al., 2014; Pehrson et al., 2016a).
Thus, it appears that vortioxetine is capable of producing modest
but significant improvements in some aspects of MDD-related
cognitive dysfunction.
The glutamate neurotransmitter system is the primary
excitatory drive in the mammalian central nervous system
and its integrity is crucial for proper cognitive function. In
support of this notion, experimental manipulations that reduce
glutamate receptor activation, such as the α-amino-3-hydroxy5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist
CNQX (Pierson et al., 2015), the N-methyl-D-aspartate (NMDA)
receptor antagonist MK-801 (Stefani and Moghaddam, 2010),
or the metabotropic glutamate 5 receptor (mGlu5) receptor
antagonist MPEP (Christoffersen et al., 2008), have cognition
impairing properties. Conversely, manipulations that enhance
glutamatergic activity at postsynaptic targets, such as the
AMPAkine aniracetam (Bartolini et al., 1996), the NMDA
receptor glycine site agonist D-cycloserine (Flood et al., 1992), or
the mGlu5 receptor agonist CDPPB (Fowler et al., 2013), tend
to improve cognitive function, at least within an optimal dose
window.
This laboratory has undertaken a significant effort in
understanding the mechanism of action underlying vortioxetine’s
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where the diet was removed. During training and testing, each
rat received approximately 11 g of diet per day, given after the
training and/or test sessions. Rats assigned to the sub-chronic
vortioxetine study, wherein vortioxetine was administered via
diet, had food from the appropriate drug condition ad libitum
(Purina 5001 rodent chow with or without vortioxetine mixed
into it, Research Diets, Inc., New Brunswick, NJ, United States)
until the day before the first training session. During training
and testing, rats received approximately 11 g of appropriate diet
per day.

hippocampal subregion (Nomura et al., 2016), as well as reduced
uptake of 2-deoxyglucose in the frontal cortex (Pratt et al., 2008).
Observations of reduced parvalbumin expression and
increased IPSCs recorded from pyramidal neurons apparently
contradict one another. But these competing observations may
suggest that the subPCP model is associated with a complex
dysregulation of GABAergic neurotransmission featuring both
increases and decreases in inhibitory tone, perhaps originating
from different interneuron populations. Moreover, a complex
dysregulation such as this could reasonably be expected to induce
cognitive dysfunction. If this concept is true, then vortioxetine’s
ability to suppress aspects of GABAergic neurotransmission
and concomitantly bolster glutamate neurotransmission may
represent a logical mechanism through which a portion of
subPCP-induced cognitive impairments may be attenuated.
Thus, the purpose of the current study is to evaluate
vortioxetine’s effects in the subPCP model, which represents
a biological model of cognitive impairment produced by
dysregulation of GABA and glutamate neurotransmission. We
hypothesized that subPCP treatment would cause impairments
in executive function and memory that would be associated
with changes in GABA receptor binding, and further that these
changes would be reversed by acute or subchronic vortioxetine
treatment.

Rat Object Recognition Task, and Autoradiography
Experiments
Rats utilized in the novel OR task, as well as those used
in autoradiography, PCR and Western blot experiments were
housed three per cage in Rat IVC Green Line Sealsafe plus
cages (Tecniplast USA, Philadelphia, PA, United States). Rats
were housed for approximately 1 month before initiation of
experimental procedures. Except for the first week, the rats were
handled once every second day.

Mouse Object Recognition and Object Placement
Tasks
For the mouse Object Placement Recognition and Novel Object
Recognition tests, mice were housed two per Techniplast type III
low cages (Scanbur A/S Denmark) with aspen bedding (Tapvei;
Brogaarden, DK). For environmental enrichment, animals were
given plastic igloos (Bio-Serv Mouse Igloo) and aspen bricks
(Tapvej; Brogaarden, Denmark).

MATERIALS AND METHODS
Animals
A total of 212 adult rats were used in the experiments presented
here. Of these, 128 male Long-Evans rats were used in the
attentional set shifting task, 36 male Sprague-Dawley rats
(Charles River Laboratories, Wilmington, MA, United States)
were used in the object recognition (OR) task, and 48 male
Long Evans rats (Charles River Laboratories, Wilmington, MA,
United States) were used in autoradiography. Additionally, a total
of 48 adult male C57BL/6NCrlBr mice (Charles River, Germany)
were used in OR and object placement (OP) experiments. All
animals were group housed in temperature- (20 ± 2◦ C) and
humidity-controlled (30–70%) facilities on a 12-h light/dark cycle
(lights on at 6 am). All rodent home environments consisted
of plastic shoebox cages and featured sawdust bedding and
appropriate environmental enrichments. Except where noted
otherwise, all animals had ad libitum access to food and tap
water. Specific information for animals used in each type of
experiment is listed below. All experimental procedures were
conducted in a manner that was consistent with local guidelines
on ethical research in animal subjects and were approved by the
relevant government authority or institutional animal care and
use committee prior to the start of experiments.

Compounds and Treatments
Compounds
[1-(1-phenylcyclohexyl)-piperidine
hydrochloride
(PCP)],
vortioxetine HBr and vortioxetine lactate were synthesized by H.
Lundbeck A/S. Modafinil was purchased from Seqouia Research
Products (United Kingdom). GABA, SR-95531 HBr, and
baclofen were purchased from Tocris Bioscience (Minneapolis,
MN, United States).

Radioligands
[3 H] muscimol (36.9-38.3 Ci/mmol) was purchased from Perkin
Elmer, Inc. (Waltham, MA, United States), while [3 H] CGP54626
(30 Ci/mmol) was purchased from American Radiolabeled
Chemicals, Inc. (St. Lousi, MO, United States).

Treatments
All doses listed below refer to the base, rather than the salt, of the
compound in question.
Subchronic PCP treatment: The subPCP administration
regimen used in rats was conducted as described in (Goetghebeur
and Dias, 2009), which is a reliable method for inducing deficits
in our hands. Rats in the subPCP experiments received injections
of 5 mg/mL PCP or vehicle (saline) s.c. at a 1 mL/kg injection
volume twice per day for 7 days. Subsequently, rats had a 7day washout period prior to the beginning of experiments. The
mouse subPCP regimen was conducted as described in Pedersen
et al. (2014). Briefly, mice received vehicle or PCP (1.3 mg/mL

Rat Attentional Set Shifting Task
Rats used in the attentional set shifting task were housed 2 per
cage type III Macrolon cages. The rats were given access to food
(Rats and Mice Growth and Reproduction Diet, Shanghai SLAC
Laboratory Animal Co., LTD., Songjiang, Shanghai, China) and
water ad libitum until the day before the first training session,
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Long-Evans rats (Charles River, United States) aged 5–6 weeks
when arriving at the research facility.
The attentional set-shifting test (AST) methods used here were
adapted from Goetghebeur and Dias (2009). The apparatus used
for the AST test was a 44 cm × 64 cm × 30 cm black nontransparent Perspex test box, divided into 3 equal-sized areas (a
starting area separated from a choice area subdivided in two).
In the choice area, two 11 cm diameter terracotta pots were
placed recessed into the box floor (with a 2 cm lip remaining
above the floor) and separated by a divider. Odor (oils from The
Body Shop , United Kingdom) and media cues (not previously
presented to the rats) were added to the pots.
Beginning on day 3 after the cessation of PCP administration,
rats were subjected to a habituation period and trained to dig for a
diet reward (half a Honey Loop cereal, Nestlé ) in terracotta pots
filled with sawdust. On day 7 of PCP washout, rats were subjected
to a single training session in which they were required to
discriminate between two pots in order to find the reward. These
discriminations were either based on differences in the digging
media or the pot’s odor. On day 8 rats were presented with a series
of increasingly difficult discriminations: a simple discrimination
(SD), a compound discrimination (CD), two intra-dimensional
shifts (ID1, ID2), an intra-dimensional shift reversal (ID2R),
an extra-dimensional shift (ED) and an extra-dimensional shift
reversal (EDR; see Table 1). Rats were required to meet a training
criterion before moving on to a new discrimination type (for
specifics, see Statistical Analysis, below).
The first trial of each discrimination stage was a discovery trial
in which rats were allowed to dig in both pots, and to self-correct
if digging in the wrong pot. Rats were only given one discovery
trial. The discovery trial was included in the trials to criterion if

concentration, 10 mL/kg injection volume) s.c once per day for
14 days followed by a 7-day washout prior to experimentation.
In acute vortioxetine administration experiments in rats,
vortioxetine HBr was dissolved in 20% 2-hydroxypropylβ-cyclodextrin (20%CD; parenteral grade, Roquette America,
Inc., Keokuk, IA, United States) and injected 1 h s.c. at a
volume of 1 mL/kg. For acute vortioxetine experiments in mice,
vortioxetine lactate (used due to higher solubility) was dissolved
in 10% CD and administered s.c. at a 10 mL/kg injection volume.
Acute vortioxetine doses ranged from 1 to 10 mg/kg, and this
dose range was chosen because it approximates the clinically
relevant dose range of 50–90% occupancy at the 5-HT transporter
(SERT; see Stenkrona et al., 2013; Leiser et al., 2014). For chronic
vortioxetine administration experiments, Vortioxetine HBr was
incorporated into Purina 5001 rodent chow (Research Diets, Inc.,
New Brunswick, NJ, United States) at a concentration of 0.18 g
vortioxetine/kg of food, 0.6 g vortioxetine/kg of food, or 1.8 g
vortioxetine/kg of food p.o. as described elsewhere (Wallace et al.,
2014; Waller et al., 2017). Again, this dose range was chosen
in order to approximate the clinically relevant range of SERT
occupancy (Wallace et al., 2014; Waller et al., 2017).
Modafinil was included in the current study as a positive
control compound in the attentional set shifting task. The
compound and dose was chosen for this purpose based
on previous evidence that this compound can reverse the
effects of subPCP treatment in the attentional set shifting
task (Goetghebeur and Dias, 2009). Modafinil for acute
administration was suspended in 0.5% methyl cellulose (Sigma,
Denmark) to a concentration of 32 mg/mL and administered
30 min p.o. at a volume of 2 ml/kg, for a final dose of 64 mg/kg.
Due to the short half-life of modafinil, animals in this treatment
group received a second administration of modafinil halfway
through the attentional set-shifting task. All doses refer to the
active base of each compound.
Escitalopram and ondansetron were included in the current
study in order to assess the effects of 5-HT transporter inhibition,
and 5-HT3 receptor antagonism in the attentional set shifting
task, respectively. Escitalopram and ondansetron were dissolved
in saline at a concentration of 0.5 and 1.6 mg/mL, respectively,
and administered 1 hr s.c. at a 1 mL/kg of body weight injection
volume. These conditions yielded final doses of 0.5 or 1.6 mg/kg,
respectively. These doses were chosen on the basis of previously
reported target occupancy data. 0.5 mg/kg escitalopram 1 hr s.c. is
expected to produce approximately 90% SERT occupancy (Jensen
et al., 2014), and is thus considered a clinically relevant dose of
this compound for MDD (Meyer, 2007). 1.6 mg/kg ondansetron
is expected to produce 60% or greater occupancy at the 5-HT3
receptor (du Jardin et al., 2014).

R

R

TABLE 1 | Attentional set shifting task methods.
Discrimination type

Media

Odor name
(The Body Shop)

Training

Paper confetti

Madagascan vanilla
flower

Paper Worms

Atlas Mountain Rose

Plastic Beads

No Odor

Vermiculite

No Odor

Plastic Beads

White Musk

Simple discrimination
(SD)
Compound
discrimination (CD)
Intradimensional shift 1
(ID1)
Intradimensional shift
2/Intradimensional shift
reversal (ID2/ID2R)

Behavioral Assessments
Attentional Set-Shifting Task
Three separate attentional set-shifting studies were executed,
one examining the acute effects of vortioxetine administration,
a second examining the effects of sub-chronic vortioxetine
administration, and a third examining the effects of acute
escitalopram or ondansetron treatments. Each test used male
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Extradimensional
shift/Extradimensional
reversal (ED/EDR)

Vermiculite

Sandalwood Ginger

Lava Balls

Cranberry

Pills

Satsuma

Plastic caps

Vanilla and Tonka Bean

Paper clips

Lavender

Wall Plugs

Exotic

Catrine Pearl Litter

Amazonian Wild Lily

Order of discriminations and example stimuli.
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object was not considered an exploratory behavior. An animal
was excluded from the study if it failed to accumulate a total
exploration time > 6 s, failed to explore both objects, knocked
an object over, or jumped out of the arena.
Rats used in the OR task were subjected to the sub-chronic
PCP regimen as described above. After the 7 days washout period,
NOR testing was performed as previously described by (Redrobe
et al., 2012). On day 7 after cessation of PCP treatment, each rat
was given a habituation trial, where it was individually placed in
the open field for 5 min of free exploration. Beginning on day
8 of PCP withdrawal, rats received acute injections of vehicle
or 10 mg/kg vortioxetine s.c. 1 h prior to the training session.
Thus, the treatment groups in this experiment were as follows:
Veh/Veh, PCP/Veh, or PCP/10 mg/kg vortioxetine.
In the training session, each rat was re-habituated to the open
field for 1 min. The rat was then placed in a holding cage while
two identical objects were positioned in the open field for the OR
task information trial (IT). Subsequently, the rat was positioned
facing the wall and allowed to freely explore for 15 min. Upon
completion, the rat was returned to its home cage and remained
in the testing room during the retention period. The retention
trial (RT) occurred 45 min after completing the IT. Two objects
were again placed in the arena, one identical to the objects
used during training and one novel. The placement of the novel
object was pseudo-randomly assigned (left or right) and counterbalanced for each treatment group. The rat was positioned facing
the wall and was allowed to freely explore for 3 min.

the rat dug first in the correct pot, but not if the rat self-corrected
an incorrect initial dig. If a rat showed no interest in the pots (no
digging or sniffing in either of the pots) for more than 15 min, it
was returned to the home cage to rest for approximately 30 min
before resuming the test.
In the acute vortioxetine study, prior to the start of behavioral
experiments on Day 8 of washout from PCP treatment, animals
were randomly administered either 20% CD (Veh), vortioxetine
at 1, 3, or 10 mg/kg 1 h s.c., or 64 mg/kg modafinil 30 min p.o.
as described above (included as a positive control). Thus, the
treatment groups in the acute vortioxetine study were as follows:
Veh/Veh, PCP/Veh, PCP/1 mg/kg vortioxetine, PCP/3 mg/kg
vortioxetine, PCP/10 mg/kg vortioxetine, or PCP/64 mg/kg
modafinil.
For the sub-chronic vortioxetine administration study, rats
had ad libitum access to either vehicle food (Purina 5001) or
Purina 5001 food infused with either 0.22 g vortioxetine/kg of
food weight, or 1.8 g vortioxetine/kg of food weight. Food dosing
lasted from the first day of sub-chronic PCP administration
and until the last day of the washout period (total of 14 days).
After the end of the washout period where behavioral testing
started, rats were fed with the same conditioned diet, however,
under food restriction (∼11 g of diet per day per rat). In
addition, some PCP-treated animals were fed vehicle food, but
received acute injections of either 10 mg/kg vortioxetine, or
64 mg/kg modafinil, as described above. The treatment groups
for the subchronic vortioxetine administration study were as
follows: Veh/Veh, PCP/Veh, PCP/0.22 g/kg vortioxetine food,
PCP/1.8 g/kg vortioxetine food, PCP/10 mg/kg vortioxetine 1 h
s.c., or PCP/64 mg/kg 30 min p.o.
A third experiment was conducted to examine the effects
of acute SERT inhibition or 5-HT3 receptor antagonism on
subPCP-induced AST impairments. Acute dosing was conducted
as described above for the acute vortioxetine dosing experiment,
however, animals were randomly assigned to receive acute
vehicle, escitalopram, ondansetron, or modafinil treatment.
Thus, the treatment groups on this experiment were as follows:
Veh/Veh, PCP/Veh, PCP/1.6 mg/kg ondansetron 1 h s.c., PCP/
0.5 mg/kg escitalopram 1 h s.c., or PCP/64 mg/kg modafinil
30 min p.o.

Mouse Object Placement and Object Recognition
Tasks
Object placement and OR tasks in mice were executed in Perspex
boxes measuring 40 × 40 cm with dark gray walls and a white
floor. The tests were conducted during the light phase, yet in
a subdued light (≈20 lux) and with the radio turned on in the
background. Each trial was recorder by a camera mounted above
the test arenas and later scored manually.
Objects in the mouse OP task consisted of small stork
sculptures made of plaster, which were 11.5 cm in height, with
a roughly rectangle-shaped base 7.5 cm in length and 4.8 cm
in width. For the mouse OR task, objects consisted of (1)
small cylindrical pepper mills (purchased empty, having never
contained spice) made of clear plastic (10.5 cm in height, 4.5 cm
diameter), and (2) small salt shakers made of light blue glass
(again, purchased empty; 11.5 cm in height, 4.5 cm diameter). All
objects were purchased at the dollar store.
One batch of mice was tested in both OP and OR. At
day 1 of the washout period (first day post sub-chronic PCP
administration), an s.c. bolus injection of vortioxetine 10 mg/kg
was administered. Afterward, vortioxetine (0.6 g/kg Purina 5001
rodent chow) was administered p.o., starting at day 2 of the
washout period and throughout the washout and testing period.
On the day of OP testing, animals had received the s.c. bolus
injection plus seven days of the vortioxetine-infused diet. On the
day of OR testing, mice had received the s.c. bolus injection plus
13 (and 14) days of vortioxetine infused food.
The OP protocol was a modified version of the protocol
described in Ennaceur and Meliani (1992). Mice were placed

Rat Object Recognition Task
The behavioral procedures for the rat OR task were conducted
as described in du Jardin et al. (2014). The rat OR task was
performed in a 49 cm × 49 cm × 37 cm plastic open field
apparatus. The room housing the open field apparatus was kept
under consistent, dim lighting, with an intensity of approximately
5 lux, and a radio played music softly for background noise.
Objects used in this experiment included round, green, glass vases
(diameter 5.7 cm, height 12 cm) and round, white, tin cookie
jars (diameter 6.5 cm, height 8 cm). This object pairing was
validated prior to use, in order to ensure no inherent bias existed
toward either object in the pair. OR task sessions were recorded
by a digital camera situated above the open field. Exploration
time for each object was recorded with a stopwatch from the
videos. Exploration was defined as directing the nose toward an
object at a close distance or touching the object. Sitting on the
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quickly and gently removed from the skull, flash frozen on
powdered dry ice, and stored at −20◦ C until sectioning. Later,
12 µm coronal sections were collected from an area ranging
from approximately +4.2 mm to +2.3 mm anterior to Bregma
(Paxinos and Watson, 1998) using a cryostat (MicroM, Germany)
and were thaw-mounted on glass microscope slides. This range
of coronal slices was chosen in order to study the prelimbic and
infralimbic subregions of the medial prefrontal cortex, given the
importance of these regions in tests of executive function such as
the attentional set shifting task (Ng et al., 2007). After the tissue
mounted on the microscope slides had dried thoroughly (in order
to reduce damage from freezing), slides were packed into slide
boxes with desiccator pellets, and stored at −20◦ C for use in EVA
saturation binding and competition experiments.
Each of the EVA procedures used in this study are variations
on a similar theme. On the day of an experiment, slide-boxes were
defrosted under a constant stream of air at room temperature
until the boxes were dry and equilibrated with the environment
in terms of temperature. This step was undertaken in order to
ensure brain tissue was not damaged by frosting due to a sudden
change in humidity. Prior to any binding experiments, slides were
preincubated in the appropriate preincubation buffer and dried
at room temperature. Subsequently, tissue was incubated in an
assay buffer containing a radioligand appropriate for the receptor
of interest, then rinsed in assay buffer, and dried overnight in a
vacuum desiccator. Specific information on the contents of the
preincubation buffers, assay buffers and other assay conditions
are listed in Table 2. Finally, slides were opposed to a tritiumsensitive phosphor screen (Fuji imaging plate, GE Healthcare,
Pittsburgh, PA, United States) for 5 days before being read in a
phosphorimager (Typhoon FLA7000, GE Healthcare). Analysis
methods are listed below under statistical analyses.
Competition binding experiments were conducted in order
to determine the Ki of GABA at each receptor target. In
these experiments, the concentration of the relevant radioligand
remained constant, but varying concentrations of GABA

individually in the test arena for a 4-min acquisition trial. During
the IT, two identical objects were situated in each of the arena’s
front corners, 10 cm from the walls. Upon completion, the mouse
was returned to its home cage and remained in the testing room
during the period. In the RT, which occurred 1 h after the
completion of the IT, the same to objects were situated in the
arena, however, one of the objects were placed in one of the back
corners (10 cm from the walls), opposite to the object placed
in the front corner. The position of the objects was pseudorandomly assigned (left or right) and counter-balanced for each
treatment group.
During the acquisition trial and the test trial, cues were
mounted at all four walls, to allow mice to orient themselves in
the test arena. Cues were made in office PowerPoint, where white
shapes were placed on a black background (cue 1: Two stars,
cue 2: three vertical stripes, cue 3; one big arrow and cue 4: three
smileys).
The OR testing was performed by giving the mice a 3 min IT
with two identical objects. Mice were then returned to their home
cages for 1 h, before being placed back in the test arena facing the
wall for a 3 min RT. During the RT, one object was replaced with
a novel object. Object pairs were validated prior to use to ensure
no bias existed toward one of the objects in the pair. The position
of the novel object was pseudo-randomly assigned (left or right)
and counter-balanced for each treatment group. Mice that did not
explore each object for a minimum of 2 s were excluded from
further analysis.

Ex Vivo Autoradiography
Rats used in ex vivo autoradiography (EVA) experiments
were randomly assigned to one of four experimental groups
characterized by either subchronic saline or PCP (as described
above) along with either vehicle or vortioxetine-infused food
(1.8 g vortioxetine/kg food weight, as described in the attentional
set shifting task). On day 8 of PCP withdrawal, rats were
anesthetized using CO2 and killed by decapitation. Brains were
TABLE 2 | Ex vivo autoradiography experiment methods.
Target receptor

GABAA receptor

GABAB receptor

Assay

Saturation binding

Competition binding

Saturation binding

Competition binding

Preincubation Buffer

50 mM Tris Citrate
(pH = 7.1)
150 mM NaCl

50 mM Tris Citrate
(pH = 7.1)
150 mM NaCl

120 mM NaCl
6 mM Glucose
20 mM Tris HCl
4.7 mM KCl
1.8 mM CaCl2 2H2 O
1.2 mM KH2 PO4
1.2 mM MgSO4

120 mM NaCl
6 mM Glucose
20 mM Tris HCl
4.7 mM KCl
1.8 mM CaCl2 2H2 O
1.2 mM KH2 PO4
1.2 mM MgSO4

Preincubation time

30 min

30 min

15 min

15 min

Assay Buffer

50 mM Tris Citrate
(pH = 7.1)

50 mM Tris Citrate
(pH = 7.1)

Same as preincubation
buffer

Same as preincubation
buffer

Radioligand

[3 H]muscimol

10 nM [3 H]muscimol

[3 H]CGP54626

3 nM [3 H]CGP54626

Competitor/Non-specific
binding agent

1 µM SR95531

GABA

10 µM baclofen

GABA

Incubation time

40 min

40 min

2h

2h

Rinse (in assay buffer)

3 × 5 min

3 × 5 min

2 × 15 min

2 × 15 min

Rinse temperature

4◦ C

4◦ C

RT

RT
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(ranging from 0.3 nM to 100 µM in half log steps) was included
in the assay buffer.
In saturation binding experiments, the concentration of the
relevant radioligand in the assay buffer was systematically varied
in order to determine the KD and Bmax of the receptor in
question. At each radioligand concentration, the non-specific
binding was determined on a separate slide by including a high
concentration of a non-radioactive competitor ligand in the
assay buffer along with the radioligand. For GABAA receptor
saturation binding experiments, [3 H]muscimol was examined in
quarter log steps ranging from 0.56 to 300 nM. For GABAB
receptor saturation binding experiments, [3 H]CGP54626 was
examined in quarter log steps ranging from 0.17 to 100 nM.

ImageQuant software (GE Healthcare Life Sciences, Pittsburgh,
PA, United States).
For GABA competition binding studies, the primary
dependent measure was pKi. Ki values for competition
experiments were calculated separately for each animal, then
aggregated to estimate sample averages and error. Ki values
were calculated via non-linear regression, assuming a one-site
competition binding, using GraphPad Prism version 6 for
Windows (GraphPad software, La Jolla, CA, United States).
pKi values were then calculated via the following formula:
pKi = −Log10 (Ki).
For saturation binding studies, the primary dependent
measures were pKD and Bmax. First, a standard curve was
generated by measuring optical intensity from a slide of tritium
standards (American Radiolabeled Chemicals, St. Louis, MO,
United States) included in the slide cassette during exposure.
A linear regression was performed to determine the relationship
between intensity and bound radioactivity (measured on the
standards in units of µCi/g). Next, average intensity values
from the non-specific bound condition for each concentration
of radioligand was subtracted from intensity values from the
total bound condition to produce a measure of specific binding
for each radioligand concentration. These optical intensity
values were transformed into bound radioactivity (expressed as
nCi/mg) measurements by interpolation from the standard curve
noted above. Finally, these values were further transformed by
multiplying by the inverse of the relevant radioligand’s specific
radioactivity (expressed as nCi/fmol). Thus, the final bound
radioactivity data was expressed as fmol of radioligand/mg of
tissue. KD and Bmax values were calculated from these specific
bound radioactivity data via non-linear regression, assuming a
one-site saturation curve, using GraphPad version 6. pK D values
were calculated from K D values as described above for pKi.

Statistical Analysis
General Data Processing and Statistical Analysis
All data in this study was analyzed using similar overall
procedures. First, the Lilliefors test was used to examine whether
data was distributed normally. In cases where the data was
normally distributed, the data was examined for outliers using
Peirce’s Criterion (Ross, 2003). Finally, data was analyzed
for group differences using a suitable analysis of variance
(ANOVA) model, followed by Tukey–Kramer post hoc tests
where appropriate. For all statistical tests, statistical significance
was set at p < 0.05. All statistical analyses were conducted using
R (R Core Team, 2017), except where noted below.

Attentional Set-Shifting Task
The primary dependent measure for the attentional set shifting
test was the number of trials required for an animal to reach
the criterion of six consecutive correct trials. Set shifting data
was analyzed using a two-way mixed repeated measures ANOVA,
with discrimination type as a repeated measures factor and
treatment as a between-subjects factor. This analysis structure
is commonly used for similarly designed AST experiments
(Redrobe et al., 2012; Maeda et al., 2014).

RESULTS
Attentional Set-Shifting Task in Rats

Object Recognition and Object Placement Tasks

Acute Vortioxetine Experiments

The primary dependent measure for the OR and object placement
tasks was a novel object or novel placement preference score,
which were calculated from raw object investigation times using
the following equation: Preference Score = ITN /(ITN + ITF )∗ 100,
where ITN represents the investigation time for the novel
object or placement, and ITF represents the investigation for
the familiar object or placement. Total exploration times from
the information and test trials were analyzed for OP and OR
experiments. Preference score and total exploration time data
was analyzed for treatment group differences using a one-way
between-subjects ANOVA. This analysis structure is similar to
that used in previous studies with similar experimental designs
(du Jardin et al., 2014; Jensen et al., 2014).

Figure 1 illustrates the effects of acute vortioxetine treatment
on subPCP-induced impairments in the AST. The treatment
main effect was non-significant [F(5,55) = 1.2, n.s.], however,
we observed a significant main effect of discrimination
type [F(6,330) = 92.95; p < 0.001], and a significant
discrimination type × treatment interaction [F(30,330) = 2.079;
p < 0.01]. Post hoc tests revealed a significant increase in
trials to reach criteria in the ED discrimination stages in
the subPCP/vehicle group compared to the vehicle/vehicle
group (p < 0.01), indicating a subPCP-induced impairment.
Within the ED discrimination (Figure 1A), this impairment
was significantly reversed in the subPCP/acute vortioxetine
treatment groups at the 1, 3, and 10 mg/kg 1 h s.c. doses,
and in the subPCP/acute 64 mg/kg modafinil 30 min p.o.
treatment group (p < 0.05 – 0.001). Within the EDR
discrimination (Figure 1B), subPCP treatment induced
significant increases in the number of trials required to meet
criterion. However, neither acute vortioxetine nor modafinil

Autoradiography Data
There were three primary dependent measures for the
autoradiography data, all of which were derived from intensity
measurements obtained by analyzing phosphor screens using
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FIGURE 1 | Acute vortioxetine administration reverses a subset of subchronic PCP (subPCP)-induced deficits in the attentional set shifting test (AST). SubPCP
treatment induced significant impairments in the extradimensional shift (A) and extradimensional reversal (B) discriminations of the AST. Acute treatment with
vortioxetine significantly reversed subPCP-induced impairments in the extradimensional shift at 1, 3, and 10 mg/kg 1 h s.c. Additionally, acute modafinil treatment at
64 mg/kg 30 min p.o. significantly reversed subPCP induced extradimensional shift impairments. However, neither acute vortioxetine treatment at these doses nor
acute modafinil treatment significantly altered the subPCP-induced impairment in the extradimensional reversal discrimination. Data are presented as mean ± SEM.
Asterisks represent significant differences from the Veh/Veh treatment group (∗ p < 0.05; ∗∗ p < 0.01). Number signs represent significant differences from the
PCP/Veh treatment group (# p < 0.05; ## p < 0.01; ### p < 0.001). Final group sample sizes were as follows: Veh/Veh: n = 10; PCP/Veh: n = 12; PCP/1Vor: n = 10;
PCP/3Vor: n = 10; PCP/10Vor: n = 10; PCP/Mod: n = 9.

significantly reversed subPCP-induced impairments in this
discrimination.

acute treatment with 64 mg/kg modafinil significantly improved
performance in both discriminations (p < 0.001 for all groups).

Subchronic Vortioxetine Experiments

Acute Ondansetron and Escitalopram Experiments

Figure 2 represents the effects of subchronic treatment with
vortioxetine on subPCP induced impairments in the AST.
For these data, we observed a significant main effect of
treatment [F(5,60) = 3.08, p < 0.05], a significant main effect
of discrimination type [F(6,360) = 119.64; p < 0.001] and a
significant discrimination type × treatment interaction effect
[F(30,360) = 2.1; p < 0.001]. Post hoc analysis revealed that
subPCP treatment induced an impairment in AST performance,
shown as a significant increase in trials to reach criteria in
the ED (Figure 2A) and EDR (Figure 2B) discriminations
(p < 0.001). In each case, the subPCP-induced impairments
were significantly attenuated by treatment with subchronic
low-dose (0.18 g vortioxetine/kg food weight) and high-dose
(1.8 g vortioxetine/kg food weight) vortioxetine (p < 0.001). In
addition, acute treatment with 10 mg/kg vortioxetine 1 h s.c.
also induced a significant normalization of AST performance
in subPCP-treated rats in both the ED and EDR tasks. Finally,

Figure 3 shows the effects of acute treatment with the
5-HT3 receptor antagonist ondansetron, the SERT inhibitor
escitalopram, and modafinil on subPCP-induced impairments
in AST performance. Once again, we observed a significant
treatment main effect [F(4,55) = 2.97, p < 0.05], a significant
discrimination type main effect [F(6,330) = 130.41, p < 0.001],
and a significant discrimination type x treatment interaction
[F(24,330) = 2.59, p < 0.001]. Post hoc testing in the ED
discrimination (Figure 3A) found that subPCP induced
a significant increase in the number of trials required
to reach criterion compared to the vehicle/vehicle control
group (p < 0.001). Additionally, subPCP-treated rats acutely
administered ondansetron at 1.6 mg/kg (p < 0.05), escitalopram
at 0.5 mg/kg (p < 0.001), or modafinil (p < 0.001) exhibited
significant reductions in the trials to criterion dependent
measure compared to PCP/vehicle-treated rats. In the EDR
discrimination, subPCP treatment failed to induce a significant
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FIGURE 2 | Subchronic vortioxetine treatment blocks subPCP-induced deficits in the AST. SubPCP treatment induced significant impairments in the AST
extradimensional shift (A) and extradimensional reversal discriminations (B). Subchronic treatment with vortioxetine at 0.18 g vortioxetine/kg of food weight (Low
Vor), or 1.8 g/kg vortioxetine p.o. (Hi Vor) blocked subPCP-induced impairments in both discriminations. Additionally, acute treatment with 10 mg/kg vortioxetine 1 h
s.c. or 64 mg/kg modafinil 30 min p.o. replicated its ability to reverse subPCP-induced extradimensional shift impairments, and also reversed subPCP-induced
impairments in the extradimensional reversal test. Data are presented as mean ± SEM. Asterisks represent significant differences from the Veh/Veh treatment group
(∗∗∗ p < 0.001). Number signs represent significant differences from the PCP/Veh treatment group (## p < 0.01; ### p < 0.001). Final group sample sizes were as
follows: Veh/Veh: n = 11; PCP/Veh: n = 12; PCP/LowVor: n = 12; PCP/HiVor: n = 12; PCP/10Vor: n = 9; PCP/Mod: n = 10.

Analysis of total exploration times in the training
[F(2,31) = 0.7, n.s.] and test sessions [F(2,31) = 1.42, n.s.]
revealed no significant group differences (see Supplementary
Table S1).

increase in the number of trials required to meet criterion
compared to the vehicle/vehicle animals. Animals in the
PCP/ondansetron or PCP/escitalopram treatment groups did
not differ with respect to the trials to criterion dependent measure
when compared with either the vehicle/vehicle or PCP/vehicle
treatment groups. However, rats in the PCP/modafinil treatment
group reached criterion in significantly fewer trials than animals
in the vehicle/vehicle or PCP/vehicle groups (p < 0.05).

Object Recognition Task in Mice
Figure 5A represents OR task novel object preference
scores in mice treated with vehicle/vehicle, subPCP/vehicle,
vehicle/vortioxetine, or subPCP/vortioxetine. A one-way
ANOVA revealed a significant relationship between treatment
group and OR performance [F(3,40) = 9.19, p < 0.001].
Post hoc tests showed that animals in the subPCP/veh group
had significantly lower novel object preference scores than
control animals (p < 0.001). SubPCP/vortioxetine animals
had significantly higher novel object preference scores than
subPCP/vehicle animals (p < 0.01). There was no statistically
significant difference in novel object preference scores between
the vehicle/vehicle and vehicle/vortioxetine treatment groups.
Analysis of total exploration times in the training
[F(3,39) = 0.6, n.s.] and test sessions [F(3,39) = 2.24, n.s.]

Object Recognition Task in Rats
In this portion of the study, we investigated the effects of
treatment with subPCP alone or in combination with 10 mg/kg
vortioxetine 1 h s.c. on OR performance in rats. Analysis
of preference score data using one-way ANOVA revealed a
significant main effect of treatment group [F(2,31) = 5.47,
p < 0.01]. As shown in Figure 4, post hoc analysis revealed
that subPCP treatment alone induced significant impairments in
OR performance compared to vehicle-treated controls that was
significantly attenuated by acute 10 mg/kg vortioxetine treatment
(p < 0.05 for both effects).
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FIGURE 3 | Acute treatment with ondansetron or escitalopram reverses subPCP induced deficits in the extradimensional shift discrimination of the AST. SubPCP
treatment induced a significant impairment in the extradimensional shift discrimination (A), but not in the extradimensional reversal (B). Acute treatment with
1.6 mg/kg ondansetron (1 h s.c.) or 0.5 mg/kg escitalopram (1 h s.c.) significantly reversed the subPCP-induced deficit in the extradimensional shift. Acute treatment
with modafinil also reversed subPCP-induced extradimensional shift impairment, and improved performance compared to both the Veh/Veh group and the PCP/Veh
group in the extradimensional reversal discrimination. Data are presented as mean ± SEM. Asterisks represent significant differences from the Veh/Veh treatment
group (∗ p < 0.05; ∗∗∗ p < 0.001). Number signs represent significant differences from the PCP/Veh group (# p < 0.05; ### p < 0.001). Final group sample sizes were
as follows: Veh/Veh: n = 12; PCP/Veh: n = 12; PCP/Ond: n = 12; PCP/Esc: n = 12; PCP/Mod: n = 12.

revealed no significant treatment group differences (see
Supplementary Table S2).

once again revealed no significant treatment group differences
(see Supplementary Table S2).

Object Placement Task in Mice

GABAA and GABAB Receptor
Autoradiography in the Rat Medial
Prefrontal Cortex

Figure 5B shows OP task performance in mice in the same
treatment groups noted above for the mouse OR task. Once
again, a one-way ANOVA revealed a significant relationship
between treatment group and object placement task performance
[F(3,41) = 5.7, p < 0.01]. Further analysis demonstrated once
again that animals in the subPCP/vehicle group had significantly
reduced novel placement preference scores by comparison to
vehicle/vehicle control animals (p < 0.01). Acute treatment
with vortioxetine significantly attenuated the object placement
task impairment induced by subPCP treatment (p < 0.05).
Animals in the vortioxetine/vehicle group exhibited significantly
higher object placement task performance than subPCP/vehicletreated animals, but did not perform significantly better than
vehicle/vehicle control subjects.
Analysis of total exploration times in the training
[F(3,41) = 0.6, n.s.] and test sessions [F(3,41) = 0.59, n.s.]
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Table 3 shows the effects of subPCP, vortioxetine or combinations
thereof on pKi, pKD , and Bmax data for GABAA or GABAB
receptor ligands in the prelimbic and infralimbic subregions of
the rat medial prefrontal cortex.

GABAA Receptors
Analysis of GABA pKi data at the GABAA receptor
uncovered a statistically significant main effect of treatment
type [F(3,43) = 8.657, p < 0.001]. Post hoc analysis
found that animals in the vehicle/vortioxetine treatment
group had a significantly greater pKi compared to those
in the saline/vehicle group (p < 0.01), representing an
approximately 2.5-fold increase in the affinity of GABA for
the GABAA receptor. GABA pKi values from animals in the
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FIGURE 4 | Acute vortioxetine reverses subPCP-induced object recognition task impairments. SubPCP treatment induced a significant deficit in object recognition
performance, which was reversed by acute administration of 10 mg/kg vortioxetine (1 h s.c.). Data are presented as mean ± SEM. Asterisks represent significant
differences from the Veh/Veh treatment group (∗ p < 0.05). Number signs represent significant differences from the PCP/Veh group (#p < 0.05). Final group sample
sizes were as follows: Veh/Veh: n = 11; PCP/Veh: n = 11; PCP/10Vor: n = 12.

were independently sufficient to recapitulate this effect. In
addition, we demonstrated that acute vortioxetine reversed
subPCP-induced impairments in the rat OR task, and that
subchronic vortioxetine blocked subPCP-induced impairments
in the mouse OR and placement tasks. Autoradiographic data
suggests that subchronic vortioxetine treatment induced a
modest but significant increase in the affinity of GABA for the
GABAA receptor that was not present when vortioxetine was
co-administered with PCP. The combination of subPCP and
vortioxetine was also associated with reduced affinity of the
GABAA receptor orthosteric site-selective ligand [3 H]muscimol.
Finally, subchronic PCP induced a reduction in GABAB receptor
expression that was insensitive to subchronic treatment with
vortioxetine. However, we find that the relevance of these
changes in GABA receptor biology for cognitive function is
unclear.

PCP/vortioxetine group were significantly lower than the
vehicle/vortioxetine group (p < 0.01), but were not significantly
different than other groups. SubPCP treatment on its own
did not significantly alter GABA pKi values as assessed
here.
Analysis of [3 H]muscimol pKD data also found a statistically
significant main effect of treatment [F(3,42) = 7.849, p < 0.001],
which was driven by a small but significant reduction
in [3 H]muscimol affinity for the GABAA receptor in the
PCP/vortioxetine group by comparison to all other treatment
groups. No other significant group differences were observed in
the pKD data. Finally, analysis of Bmax values for [3 H]muscimol
found no significant differences [F(3,44) = 2.14, n.s.].

GABAB Receptors

Analysis of GABA pKi and [3 H]CGP54626 pKD data for
GABAB receptors found no significant effects of treatment group
[F(3,42) = 1.491, n.s. and F(3,42) = 1.982, n.s., respectively].
However a significant main effect of treatment was found
in the [3 H]CGP54626 Bmax data [F(3,42) = 6.4, p < 0.01].
Further analysis revealed that subPCP treatment led to significant
reductions in Bmax values compared to the saline/vehicle group
(p < 0.05). This reduction was maintained in PCP/vortioxetine
treated animals (p < 0.001), however, no significant differences
were observed between the PCP/vehicle and PCP/vortioxetine
groups.

Vortioxetine Attenuates
SubPCP-Induced Impairments in the
Attentional Set-Shifting Task
Consistent with literature reports, subPCP treatment induced a
reliable impairment in AST performance that was selective for the
ED discrimination, and induced less reliable EDR discrimination
impairments (Rodefer et al., 2005, 2008; Goetghebeur and
Dias, 2009; Redrobe et al., 2012). Also consistent with
literature findings, acute modafinil administration reliably
reversed subPCP-induced impairments in the ED discrimination
(Redrobe et al., 2012).
Acute vortioxetine administration (1, 3, and 10 mg/kg, 1 h
s.c.), which encompasses the majority of the clinically relevant
dose range of 50–90% SERT occupancy (Stenkrona et al., 2013;
Leiser et al., 2014) significantly attenuated the subPCP-induced
deficit in the ED but not the EDR discrimination. Although, it
should be noted that the 10 mg/kg dose was able to attenuate

DISCUSSION
In the present study, we demonstrated that acute or subchronic
vortioxetine treatment attenuated subPCP-induced impairments
in the attentional set shifting task in rats, and that acute
administration of either the 5-HT3 receptor antagonist
ondansetron or the selective SERT inhibitor escitalopram
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FIGURE 5 | Subchronic vortioxetine treatment in mice blocks subPCP-induced impairments in the object recognition and object placement tasks. Subchronic PCP
treatment induced a significant impairment in object recognition performance (A), and object placement performance (B). Animals in the vehicle/vortioxetine
treatment group performed significantly better than subPCP/veh-treated animals in both tasks but did not perform differently from veh/veh controls. However,
subPCP/vortioxetine-treated animals also performed significantly better than subPCP/veh-treated animals in both tasks. mean ± SEM. Asterisks represent
significant differences from the Veh/Veh treatment group (∗∗ p < 0.01). Number signs represent significant differences from the PCP/Veh group (# p < 0.05;
### p < 0.001). Final group sample sizes were as follows: object recognition: Veh/Veh: n = 11; PCP/Veh: n = 11; Veh/Vor: n = 11; PCP/Vor: n = 10. object placement:
Veh/Veh: n = 11; PCP/Veh: n = 10; Veh/Vor: n = 12; PCP/Vor: n = 12.

negligible. To assess the relevance of these two mechanisms a
separate experiment was undertaken using the selective 5-HT3
receptor antagonist ondansetron (1.6 mg/kg 1 h s.c., estimated
5-HT3 receptor occupancy 60–65%; du Jardin et al., 2014),
and the selective SERT inhibitor escitalopram (0.5 mg/kg 1 h
s.c., estimated SERT occupancy 90%; Jensen et al., 2014) on
subPCP-induced AST impairments. Acute administration of
either ondansetron or escitalopram were independently capable
of reversing subPCP-induced impairments in this task.

subPCP-induced impairments in the EDR in one of the two
experiments in which it was used. Subchronic vortioxetine
administration at 0.22 g vortioxetine/kg of food weight (p.o. ad
libitum) and 1.8 g vortioxetine/kg of food weight, which covers
the entire clinically relevant dose range (Wallace et al., 2014;
Waller et al., 2017), blocked subPCP-induced impairments in
both the ED and EDR discrimination.
The fact that low vortioxetine doses (acute 1 mg/kg, subchronic 0.22 g/kg food) attenuated the effects of subPCP on AST
performance may provide a hint at the mechanisms underlying
its beneficial effects in this model. At the 1 mg/kg acute dose,
vortioxetine exhibits full occupancy at the 5-HT3 receptor, where
it acts as an antagonist, and 60–65% occupancy at the SERT
(Leiser et al., 2014). Similarly, the 0.22 g/kg subchronic dose
exhibit full occupancy at 5-HT3 receptors and approximately 50%
occupancy at the SERT (SERT occupancy: Waller et al., 2017;
5-HT3 receptor occupancy estimated based on known SERT:5HT3 receptor occupancy relationships; Leiser et al., 2014). In
each case, occupancy at vortioxetine’s other receptor targets is
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5-HT3 Receptor Antagonism: A Possible
Role for Suppressing Non-parvalbumin
Expressing GABAergic Interneurons in
Attenuating SubPCP-Induced Cognitive
Deficits
Ondansetron’s ability to reverse subPCP-induced impairments
is particularly interesting. 5-HT3 receptors in the frontal cortex
are thought to be exclusively expressed on a subset of non-PVIR
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exclusive. PV-IR and non-PV-IR cells are separate neural
populations with different roles in information processing,
and thus it is possible that subPCP treatment regulates
each of these populations in complex and opposing ways,
including suppressed GABAergic neurotransmission from
PV-IR fast spiking cells directed at the soma and axon initial
segment of principal cells, and perhaps increased GABAergic
neurotransmission directed toward principal cell dendritic
arbors. However, this concept is speculative and should
be viewed with caution until more supporting data can be
produced.

GABAergic interneurons (Puig et al., 2004), where they act as a
source of serotonin-mediated excitatory drive. 5-HT3 receptor
antagonism is thought to suppress the GABAergic cell firing
and drive down inhibitory postsynaptic currents (IPSCs) from
pyramidal neurons (Dale et al., 2014), and thereby increase
cortical pyramidal neuron firing (Riga et al., 2016). Similar
effects have been observed with acute or subchronic vortioxetine
treatment (Riga et al., 2016, 2017), but not escitalopram (Riga
et al., 2017). Taken together with the effects of ondansetron in
subPCP-treated animals in the AST task, these data open for
the possibility that suppressing GABAergic neurotransmission
stemming from non-PVIR sources mediates reversal of
subPCP-induced cognitive impairments. This concept is further
supported by data showing that negative allosteric modulation
of α5 subunit-containing GABAA receptors using RO4938581
significantly attenuated subPCP-induced impairments in the
ED and EDR discriminations of the AST, using the same
subPCP model featured in the current work (Redrobe et al.,
2012).
The idea that suppressing GABA neurotransmission improves
AST performance in subPCP-treated animals does not
require that subPCP-induced impairments are caused by
increased GABAergic neurotransmission. However, recent data
suggest that subPCP induces complex changes in GABAergic
neurotransmission, including increases and decreases from
separate neural populations. Nomura et al. (2016) found that
subPCP treatment in mice led to a significant increase in
the threshold for inducing long term potentiation (LTP; an
electrophysiological phenomenon related to plasticity that
is commonly associated with cognition) in the hippocampal
CA1 region and significant increase in IPSCs recorded from
CA1 pyramidal neurons, suggesting that at least some portion
GABAergic inhibition is increased after subPCP treatment.
Other research groups have also observed subPCP-induced
LTP impairments in the CA1 and lateral amygdala using
lower subPCP doses (Pollard et al., 2012). Interestingly, at
least one research group has observed that subPCP induces
a reduction in glucose metabolism in the medial prefrontal
cortex in rats (Cochran et al., 2003). Given the connection
between glutamate neurotransmission and glucose metabolism
in the brain (e.g., Patel et al., 2005), reductions in glucose
metabolism such as this could point to a reduction in principal
cell activity after subPCP treatment. These data may also
indirectly implicate a net bias toward inhibition in the
balance of excitatory and inhibitory neurotransmission in
this model. If these observations can be replicated, they may
support a role for increased GABAergic neurotransmission
from some cellular populations, although more study is
required to appropriately address this concept. However,
these data conflict with observations suggesting reduced
GABAergic neurotransmission in the subPCP model.
Suppressed expression of the calcium binding protein PV
is a common observation in subPCP-treated animals, i.e.,
reduced number, density or intensity of staining of PV-IR
cells (Schroeder et al., 2000; Cochran et al., 2003; Jenkins
et al., 2010; Pollard et al., 2012; Redrobe et al., 2012). But the
apparently conflicting data sets are not necessarily mutually
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A Role for SERT Inhibition in Regulating
SubPCP-Induced AST Impairments?
As noted above, the vortioxetine doses used involved SERT
occupancies in the range of 50–90%. In order to test the relevance
of SERT inhibition for this task, we studied escitalopram
0.5 mg/kg (ED80% occupancy = 0.3 mg/kg 1 h s.c.; Jensen et al.,
2014) in the subPCP AST. Escitalopram significantly reversed
subPCP-induced impairments.
To our knowledge, this is the first observation that a clinically
relevant dose of a selective SERT inhibitor can ameliorate
subPCP-induced AST deficits. Previous investigations have
shown that chronic treatment with citalopram or escitalopram
attenuates impairments in the AST ED discrimination induced by
chronic unpredictable stress (Bondi et al., 2008), suggesting that
escitalopram’s pharmacological properties can be relevant for this
aspect of cognition under some biological conditions. However,
we are not aware of any evidence suggesting the biological
effects of chronic stress are similar to those induced by subPCP
treatment.
We only identified one other study of the effects of SERT
inhibition on subPCP induced cognitive impairments.
Hashimoto et al. (2007) observed that single suprapharmacological doses of fluvoxamine and paroxetine (20
and 10 mg/kg; respectively; SERT occupancy ED80 ≈ 1.8 and
0.2 mg/kg, respectively; Pehrson et al., 2015) improved subtle
subPCP-induced impairments in OR performance. Repeated
administration of fluvoxamine but not paroxetine reversed
deficits in OR performance. Hashimoto et al. (2007) attributed
this effect of fluvoxamine to its agonist actions at the sigma1
receptor, since the sigma1 receptor antagonist NE-100 blocked
this effect. We regard it as unlikely that a sigma1 receptormediated mechanism is relevant for escitalopram’s effects on
subPCP-induced deficits at the 0.5 mg/kg dose in the AST.
Escitalopram’s Ki -values for the SERT and sigma 1 receptors
are reported to approximately 1 nM and 100 nM, respectively
(Sanchez et al., 2003). Based on these data and previous work
showing a SERT occupancy ED50 ≈ 0.07 mg/kg for escitalopram
(Jensen et al., 2014; Pehrson et al., 2015), we roughly estimate
escitalopram’s ED50 at the sigma1 receptor in the range of
6–8 mg/kg, or more than 10-fold above the dose used here.
Thus, we expect escitalopram’s occupancy of the sigma1 receptor
to be negligible and consider SERT inhibition the most likely
mechanism through which escitalopram is acting in this
condition. Whether escitalopram’s effects in this model are due
to a downstream effect on GABAergic and/or glutamatergic
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TABLE 3 | The effects of subchronic PCP, subchronic vortioxetine, or the combination on GABA receptor affinity and expression in the medial prefrontal cortex.
Treatment group

GABAA receptors

GABAB receptors

pKi

pKD

Bmax

pKi

pKD

Bmax

(GABA)

([3 H]muscimol)

(fmol/mg)

(GABA)

([3 H]CGP54626)

(fmol/mg)

Veh/Veh (n = 12)

6.9 ± 0.05

7.7 ± 0.03

317 ± 10

6.4 ± 0.17

8.6 ± 0.04

541 ± 38

Veh/Vor(n = 11–12)

7.3 ± 0.04a

7.8 ± 0.06

302 ± 16

6.1 ± 0.14

8.6 ± 0.08

475 ± 34

PCP/Veh(n = 10–12)

7.1 ± 0.03

7.8 ± 0.03

296 ± 13

6.0 ± 0.10

8.7 ± 0.08

414 ± 33a

343 ± 18

6.2 ± 0.09

8.7 ± 0.06

342 ± 27a,c

PCP/Vor(n = 11–12)

6.9 ±

0.08c

7.6 ±

0.03a,b,c

Subchronic treatment with vortioxetine increased the affinity of GABA for the GABAA receptor, but when administered in combination with PCP, GABA’s affinity for this
receptor was normalized. Additionally, subchronic treatment with the combination of PCP and vortioxetine induced a modest but significant reduction in the affinity of
the [3 H]muscimol for the GABAA receptor. Neither PCP nor vortioxetine altered GABAA receptor expression levels in this brain area (represented by Bmax). Neither
PCP nor vortioxetine had any significant effects on the affinity of [3 H]CGP54626 or GABA for the GABAB receptor. However, treatment with PCP significantly reduced
GABAB receptor expression levels in this brain area, independently of vortioxetine administration. Values represent the average pKD , pKi , or Bmax for the relevant
ligand ± SEM. a Represents a statistically significant difference from Veh/Veh, b Represents a statistically significant difference from PCP/Veh, c Represents a statistically
significant difference from Veh/Vor.

ability to discuss such issues here. However, from previous
work on vortioxetine’s receptor occupancy profile, we can make
some general assertions about the targets vortioxetine likely
engage at the doses used here. The acute vortioxetine dose
used in the rat OR task (10 mg/kg 1 h s.c.) engenders full
occupancy (≥80%) at 5-HT3 receptors, SERT, and 5-HT1B
receptors, and lower but potentially active occupancy levels at
5-HT1A and 5-HT7 receptors (≈40%; (Leiser et al., 2014). The
subchronic vortioxetine dose used in the mouse OR and object
placement tasks engenders full occupancy at 5-HT3 receptors and
SERT, and approximately 50% occupancy at 5-HT1B receptors
(Wallace et al., 2014; Waller et al., 2017). Occupancy at 5HT1A and 5-HT7 receptors is expected to be negligible at this
dose.
Thus, these data confirm that vortioxetine is capable of
attenuating subPCP-induced impairments in more than one
cognitive domain, and this action appears consistent across
species. However, without more data using multiple vortioxetine
doses and selective pharmacological ligands, we cannot comment
on which receptor mechanisms are relevant for vortioxetine’s
effects.

neurotransmission cannot be discerned based on the data
presented here. However, previous research demonstrates that
acute treatment with SERT inhibitors, such as escitalopram
(Riga et al., 2016) and fluoxetine (Gronier and Rasmussen,
2003) does not significantly alter frontal cortex pyramidal
neuron firing, making it unlikely that escitalopram’s effects
in this cognitive task are mediated via changes in glutamate
neurotransmission. These data, along with the consistent
improvements induced by modafinil, suggest that multiple
mechanistic avenues for improving subPCP-induced AST
impairments exist.

Vortioxetine Effects on Object
Recognition and Preference Tasks
Object recognition and object placement tasks were used as
secondary endpoints designed to examine whether vortioxetine
would ameliorate cognitive tasks disrupted by subPCP
treatment but primarily mediated by brain regions other
than the frontal cortex. Consistent with previous literature,
these experiments found that subPCP treatment significantly
impaired performance in the OR task in both rats and mice,
and in the object placement task in mice (Horiguchi et al.,
2011; Redrobe et al., 2012). Acute vortioxetine treatment
attenuated subPCP-induced OR impairments in rats and
subchronic vortioxetine attenuated subPCP-induced OR and
placement impairments in mice. In our hands, vortioxetine
has demonstrated a relatively consistent ability to improve
performance in the OR task across different impairment
models, including 5-HT-depletion (du Jardin et al., 2014;
Jensen et al., 2014), and acute scopolamine administration
(Pehrson et al., 2016a). We have also observed that vortioxetine
counteracts poor OR performance induced by long retention
intervals in normal rats (Mork et al., 2013), however, this
effect was modest, and as demonstrated in the mouse OR and
placement experiments presented here, vortioxetine does not
have a consistent ability to improve performance over control
animals.
These experiments were not designed to investigate the effects
of specific receptor mechanisms in treating subPCP-induced
OR or placement impairments, and thus we have a limited
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Autoradiographic Data: SubPCP-Induced
Increases in GABAA Receptor
Expression or Binding Were Not
Replicated
Several published studies suggest that subchronic NMDA
receptor antagonism changes GABAA receptor function. For
example, i.c.v. infusion of MK-801 (1 pmol/10 µL/h) for 7 days
elicited a significant increase in GABAA receptor binding;
assessed using the orthosteric agonist [3 H]-muscimol, and the
benzodiazepine allosteric modulator [3 H]-flunitrazepam in the
cortex and CA3 sub-region of the hippocampus (Kim et al.,
2000). These data could be interpreted either as increases
in receptor expression or affinity. Similarly, Beninger et al.
(2010) observed a significant increase in the expression of
GABAA receptors (Bmax using [3 H]muscimol as ligand) in
the frontal cortex and hippocampus, along with a reduction
in the affinity of [3 H]muscimol for GABAA receptors. Despite
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subPCP-induced impairments in animal models of executive
function and memory. In addition, 5-HT3 receptor antagonism
and SERT inhibition can independently mimic vortioxetine’s
effects on executive function. Given the many reported
aberrations observed in GABA and glutamate neurotransmission
after subPCP treatment, and separate demonstrations that
vortioxetine indirectly enhances glutamate neurotransmission
via a 5-HT3 receptor-dependent suppression of GABAergic
inhibitory drive, the data presented here further support
the notion that vortioxetine’s downstream effects on
GABA and glutamate neurotransmission are relevant for
its positive effects on cognitive function. However, we
do not regard this level of support as definitive; more
replication and extension of these data is required to fully
confirm this hypothesis. In addition, the observations
that acute escitalopram and modafinil can improve AST
performance in subPCP-treated animals suggest that multiple
mechanisms can be used to attenuate subPCP-induced cognitive
impairments.

the use of a similar subPCP dosing regimen, we did not
replicate the observation of a subPCP-induced increase in
cortical [3 H]muscimol Bmax (Table 3) seen in Beninger et al.
(2010). Thus, the consistency of subPCP-induced increases
in GABAA receptor expression is questionable. However, we
observed a significant reduction in [3 H]-muscimol affinity
for GABAA receptors in the subPCP/vortioxetine treated
group, and a statistically significant (≈2.5-fold) increase in
the affinity of the GABAA receptor for GABA in the
vehicle/vortioxetine group. Finally, we observed a significant
reduction in the expression of GABAB receptors in subPCPtreated animals that was not altered by vortioxetine treatment.
The relevance of changes in GABAB receptor expression to
cognitive function is unclear, given that this vortioxetine
dose reversed subPCP-induced impairments in the AST but
did not affect reductions in frontal cortex GABAB receptor
expression.
Assuming that vortioxetine suppresses some aspects of
GABAergic neurotransmission, then the increase in GABAA
receptor affinity for the endogenous agonist observed in
the vehicle/vortioxetine group could be interpreted as a
compensatory adaptation meant to attenuate vortioxetine’s
actions on GABA neurotransmission. A similar argument
could be made that the subPCP-induced reduction in GABAB
receptor expression is a homeostatic response to increased
GABAB receptor-mediated neurotransmission. However, given
the inconsistencies in the effects of repeated NMDA receptor
antagonism between this report and those in the published
literature, we caution against using these ideas until these data
can be replicated.
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Study Limitations and Future Studies
This study has several limitations that must be taken into
account. First, vortioxetine exhibits an approximately 10fold lesser affinity at rodent 5-HT1A and 5-HT7 receptors
by comparison to humans. Therefore, the effects of 5HT1A receptor agonism and 5-HT7 receptor antagonism have
been underestimated in these studies. Thus, the degree to
which these concepts or mechanisms translate to humans is
unknown. More work is required to fully investigate which of
vortioxetine’s mechanisms are relevant for attenuating subPCPinduced cognitive impairments, particularly in the OR and object
placement tests. Moreover, there have been some suggestions
that drugs acting on 5-HT1A receptors are relevant for some
types of cognition in schizophrenic patients (Sumiyoshi et al.,
2013), and thus future studies should examine the role of 5HT1A receptor agonism in vortioxetine’s effects in this model.
Finally, as these data are a first demonstration of vortioxetine’s
effects in the subPCP model, an independent replication is
necessary before the concepts we have advanced can be fully
accepted.
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In conclusion, acute or subchronic treatment with the
multimodal antidepressant vortioxetine significantly attenuates
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